The Healthcare and Science business of Thomson Reuters has announced the free availability of its Disease Briefing on Influenza, taken directly from Prous Science Integrity, a knowledge solution designed to empower discovery activities.
The daily briefing provides information on Influenza A (H1N1) including development pipeline for related drugs and vaccines; number of laboratory confirmed cases; international response to the pandemic; and other critical information resources. Information provided in this disease briefing uses a drug R&D approach designed for life sciences researchers, versus the medical or epidemiological approaches found elsewhere, and focuses on drugs and vaccinations that are currently in the development pipeline or on the market.
Disease Briefings are executive summaries of the current status and future trends in drug therapy for a specific disease or disorder. They provide key facts on the disease - such as risk factors, prevalence and incidence, morbidity and mortality figures, cost - along with a structured, scientific approach to the drug R&D-related aspects of diagnosis, prevention and treatment.
The Prous Science Integrity drug discovery and development portal includes 107 Disease Briefings on diseases and disorders ranging from Acne to Cancer to West Nile Fever. The Disease Briefings are fully integrated into Prous Science Integrity's suite of scientific information and tools covering the biology, chemistry and pharmacology of drug discovery and development. The portal integrates biological, chemical and pharmacological data on more than 300,000 compounds with demonstrated biological activity.
